INTRODUCTION: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. METHODS: Selective review in Medline and the data base of the American Society of Clinical Oncology on the treatment and side effects of tyrosine kinase inhibitors in renal cell carcinoma, drawing on the authors' own experience. RESULTS AND DISCUSSION: Tyrosine kinase inhibitors are characterized by a variety of uncommon side effects, such as lassitude, mucosal inflammation and skin changes. The detection and treatment of adverse events are critical for interdisciplinary cancer treatment in order to ensure patients' safety. This article offers an overview of the unwanted effects of drug therapy in the management of renal cell carcinoma.
INTRODUCTION:Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. METHODS: Selective review in Medline and the data base of the American Society of Clinical Oncology on the treatment and side effects of tyrosine kinase inhibitors in renal cell carcinoma, drawing on the authors' own experience. RESULTS AND DISCUSSION: Tyrosine kinase inhibitors are characterized by a variety of uncommon side effects, such as lassitude, mucosal inflammation and skin changes. The detection and treatment of adverse events are critical for interdisciplinary cancer treatment in order to ensure patients' safety. This article offers an overview of the unwanted effects of drug therapy in the management of renal cell carcinoma.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Vicki L Goodman; Edwin P Rock; Ramzi Dagher; Roshni P Ramchandani; Sophia Abraham; Jogarao V S Gobburu; Brian P Booth; S Leigh Verbois; David E Morse; Cheng Yi Liang; Nallaperumal Chidambaram; Janet X Jiang; Shenghui Tang; Kooros Mahjoob; Robert Justice; Richard Pazdur Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: Jayesh Desai; Leila Yassa; Ellen Marqusee; Suzanne George; Mary C Frates; Ming Hui Chen; Jeffrey A Morgan; Samuel S Dychter; P Reed Larsen; George D Demetri; Erik K Alexander Journal: Ann Intern Med Date: 2006-11-07 Impact factor: 25.391
Authors: David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Philipp Ivanyi; Thomas Winkler; Anika Grosshennig; Christoph Reuter; Axel S Merseburger; Arnold Ganser; Viktor Grünwald Journal: World J Urol Date: 2010-05-05 Impact factor: 4.226
Authors: Christine B Boers-Doets; Joel B Epstein; Judith E Raber-Durlacher; Jan Ouwerkerk; Richard M Logan; Jan A Brakenhoff; Mario E Lacouture; Hans Gelderblom Journal: Oncologist Date: 2011-12-29
Authors: Philipp Ivanyi; Thomas Fuehner; Meike Adam; Christian Eichelberg; Edwin Herrmann; Axel Stuart Merseburger; Arnold Ganser; Viktor Grünwald Journal: Med Oncol Date: 2014-08-15 Impact factor: 3.064